Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer

Drug therapies for advanced breast cancer in hormone-receptor-positive disease include both hormonal and chemotherapies. Current UK practice is to minimise toxicity by using sequential hormonal agents for as long as clinically appropriate. A Markov model was developed to investigate the cost effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameron, D A, Camidge, D R, Oyee, J, Hirsch, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607221/
https://www.ncbi.nlm.nih.gov/pubmed/19018261
http://dx.doi.org/10.1038/sj.bjc.6604790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607221/
https://www.ncbi.nlm.nih.gov/pubmed/19018261
http://dx.doi.org/10.1038/sj.bjc.6604790

Ejemplares similares